A 64-year-old male with stage IV acral-lentiginous melanoma (distant lymph node metastases) entered a clinical trial and received anti-PD1/-CTLA4 based study medication every four weeks, following the clinical trial protocol. This evidence concerns the gene CTLA4 and acral lentiginous melanoma.